Pyxis Oncology Inc. (PYXS)
| Bid | 0.87 |
| Market Cap | 54.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -0.66 |
| Forward PE | -1.2 |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 268,950 |
| Avg. Volume (20D) | 596,665 |
| Open | 0.92 |
| Previous Close | 0.94 |
| Day's Range | 0.86 - 0.94 |
| 52-Week Range | 0.86 - 5.74 |
| Beta | 1.11 |
About PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...
Analyst Forecast
According to 6 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1039.73% from the latest price.
Stock Forecasts
3 months ago · seekingalpha.com
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts AheadPyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with...